The Role of D-Dimer for Optimal Thromboprophylaxis Strategy in Patients with COVID-19

por Bhoopat, Lantarima, Martynova, Anastasia, Choi, April, Pattharanitima, Pattharawin, Han, Semi, Du, Senxi, Syed, Ibrahim, Chan, Catherine, O'Neill, Caitlin, Oh, Esther, O'Connell, Casey L.
Publicado 2020

Improving patient understanding and outcomes in myelodysplastic syndromes - An animated patient guide to MDS with visual formats of learning

por Sallman, David A., Bejar, Rafael, Montalban-Bravo, Guillermo, Kurtin, Sandra E., List, Alan F., Garcia-Manero, Guillermo, Nimer, Stephen D., O'Connell, Casey L., Schaar, Dale, Butchko, Janice, Iraca, Tracey, Searle, Stephanie
Publicado 2022

European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera

por Tremblay, Douglas, Srisuwananukorn, Andrew, Ronner, Lukas, Podoltsev, Nikolai, Gotlib, Jason, Heaney, Mark L., Kuykendall, Andrew, O’Connell, Casey L., Shammo, Jamile M., Fleischman, Angela, Mesa, Ruben, Yacoub, Abdulraheem, Hoffman, Ronald, Moshier, Erin, Zubizarreta, Nicole, Mascarenhas, John
Publicado 2022

Burnout in US hematologists and oncologists: impact of compensation models and advanced practice provider support

por Lee, Alfred Ian, Masselink, Leah E., De Castro, Laura M., Marshall, Ariela L., Connell, Nathan T., Dent, Georgette A., Fritz, Josel, Homer, Morgan, Lucas, Tiffany L., Naik, Rakhi P., Nelson, Marquita, O’Connell, Casey L., Rajasekhar, Anita, Reynolds, Robby J., Sharma, Deva, Smith, Melody, Weeks, Lachelle D., Erikson, Clese E.
Publicado 2022

Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy

por Harrison, Claire N., Garcia, Jacqueline S., Somervaille, Tim C.P., Foran, James M., Verstovsek, Srdan, Jamieson, Catriona, Mesa, Ruben, Ritchie, Ellen K., Tantravahi, Srinivas K., Vachhani, Pankit, O'Connell, Casey L., Komrokji, Rami S., Harb, Jason, Hutti, Jessica E., Holes, Leanne, Masud, Abdullah A., Nuthalapati, Silpa, Potluri, Jalaja, Pemmaraju, Naveen
Publicado 2022

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia

por Roboz, Gail J., Kantarjian, Hagop M., Yee, Karen W. L., Kropf, Patricia L., O'Connell, Casey L., Griffiths, Elizabeth A., Stock, Wendy, Daver, Naval G., Jabbour, Elias, Ritchie, Ellen K., Walsh, Katherine J., Rizzieri, David, Lunin, Scott D., Curio, Tania, Chung, Woonbok, Hao, Yong, Lowder, James N., Azab, Mohammad, Issa, Jean‐Pierre J.
Publicado 2017

Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study

por Savona, Michael R., McCloskey, James K, Griffiths, Elizabeth A., Yee, Karen, Zeidan, Amer M., Al-Kali, Aref, Deeg, H. Joachim, Patel, Prapti, Sabloff, Mitchell, Keating, Mary-Margaret, Dao, Kim-Hien, Zhu, Nancy, Gabrail, Nashat, Fazal, Salman, Maly, Joseph, Odenike, Olatoyosi, Kantarjian, Hagop, DeZern, Amy E., O'Connell, Casey L., Roboz, Gail J., Busque, Lambert, Wells, Richard A., Amin, Harshad, Randhawa, Jasleen K., Leber, Brian, Hao, Yong, Keer, Harold N., Azab, Mohammad, Garcia-Manero, Guillermo
Publicado 2021

Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study

por Garcia-Manero, Guillermo, McCloskey, James K, Griffiths, Elizabeth A., Yee, Karen, Zeidan, Amer M., Al-Kali, Aref, Deeg, H. Joachim, Patel, Prapti, Sabloff, Mitchell, Keating, Mary-Margaret, Dao, Kim-Hien, Zhu, Nancy, Gabrail, Nashat Y., Fazal, Salman, Maly, Joseph, Odenike, Olatoyosi, Kantarjian, Hagop, DeZern, Amy E., O'Connell, Casey L., Roboz, Gail J., Busque, Lambert, Wells, Richard A., Amin, Harshad, Randhawa, Jasleen K., Leber, Brian, Hao, Yong, Keer, Harold N., Azab, Mohammad, Savona, Michael R.
Publicado 2021

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

por Savona, Michael R., McCloskey, James K., Griffiths, Elizabeth A., Yee, Karen W.L., Al-Kali, Aref, Zeidan, Amer M., Deeg, H. Joachim, Patel, Prapti A., Sabloff, Mitchell, Keating, Mary-Margaret, Dao, Kim-Hien, Zhu, Nancy, Gabrail, Nashat, Fazal, Salman, Maly, Joseph, Odenike, Olatoyosi, Kantarjian, Hagop M., DeZern, Amy E., O'Connell, Casey L., Roboz, Gail J., Busque, Lambert, Wells, Richard A., Amin, Harshad, Randhawa, Jasleen K., Leber, Brian, Hao, Yong, Keer, Harold N., Azab, Mohammad, Garcia-Manero, Guillermo
Publicado 2020

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

por Mascarenhas, John, Kosiorek, Heidi E., Prchal, Josef T., Rambaldi, Alessandro, Berenzon, Dmitriy, Yacoub, Abdulraheem, Harrison, Claire N., McMullin, Mary Frances, Vannucchi, Alessandro M., Ewing, Joanne, O'Connell, Casey L., Kiladjian, Jean-Jacques, Mead, Adam J., Winton, Elliott F., Leibowitz, David S., De Stefano, Valerio, Arcasoy, Murat O., Kessler, Craig M., Catchatourian, Rosalind, Rondelli, Damiano, Silver, Richard T., Bacigalupo, Andrea, Nagler, Arnon, Kremyanskaya, Marina, Levine, Max F., Arango Ossa, Juan E., McGovern, Erin, Sandy, Lonette, Salama, Mohamad E., Najfeld, Vesna, Tripodi, Joseph, Farnoud, Noushin, Penson, Alexander V., Weinberg, Rona Singer, Price, Leah, Goldberg, Judith D., Barbui, Tiziano, Marchioli, Roberto, Tognoni, Gianni, Rampal, Raajit K., Mesa, Ruben A., Dueck, Amylou C., Hoffman, Ronald
Publicado 2022